Iparomlimab and tuvonralimab (齐倍安®) is a bifunctional combination of anti-programmed death receptor-1 (PD-1)/anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) monoclonal antibodies (mAbs) bein...

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Lou et al. report results from a multi-center single-arm phase 2 trial showing that iparomlimab and tuvonralimab (QL1706) yields promising efficacy and well-tolerable safety in previously treated patients with recurrent or metastatic cervical cancer. The high antitumor activity is irrespective of the PD-L1 status, histologic type, or prior bevacizumab treatment.